Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
06/1999
06/08/1999US5910504 Hetero-aromatic ring substituted phenyloxazolidinone antimicrobials
06/08/1999US5910479 Administering lanthocin antimicrobial in excess of minimal inhibitory concentration
06/08/1999US5910437 Ligated d-protein of formula r-l-r' where r and r' are peptides and l is linking group of thiol ester or selenol ester; for production of chirally pure chemicals and drugs; production of racemic crystals; prolonged half-life in body
06/08/1999US5910431 Polynucleotides encoding chemokine α-2
06/08/1999US5910430 Isolated nucleic acid encoding G-protein coupled receptor (HTADX50)
06/08/1999US5910414 Diagnosing bacterial infection by screening infected tissue using probes to identify nucleic acid sequences og bacterial enzyme
06/08/1999US5910310 Genetic engineered antigenic material comprising isolated whole cell culture particles as a vaccine preventing viral diseases
06/08/1999US5909734 Treatment and prevention of bacterial pneumonia; pulmonary aerosolization
06/08/1999CA2242308A1 Novel compounds
06/08/1999CA1340589C Therepeutic nucleosides
06/08/1999CA1340588C Amino acid derivatives
06/04/1999CA2253011A1 Dna encoding neospora dihydrofolate reductase-thymidylate synthase
06/03/1999WO1999027129A1 Virulence-associated nucleic acid sequences and uses thereof
06/03/1999WO1999027127A1 NOVEL ribB
06/03/1999WO1999027126A1 ribG
06/03/1999WO1999027125A1 ribA
06/03/1999WO1999027111A1 Desaturase genes and their use
06/03/1999WO1999027109A2 EXTRACELLULAR MATRIX-BINDING PROTEINS FROM $i(STAPHYLOCOCCUS AUREUS)
06/03/1999WO1999027106A1 NOVEL guaA
06/03/1999WO1999027098A2 A-33 related antigens and their pharmacological uses
06/03/1999WO1999026979A1 Lactalbumin production process
06/03/1999WO1999026971A1 Antimicrobial peptides
06/03/1999WO1999026970A1 NOVEL pth
06/03/1999WO1999026959A1 NOVEL recJ
06/03/1999WO1999026958A1 Nucleoside analog compositions and uses thereof
06/03/1999WO1999026956A1 A combinatorial library of moenomycin analogs and methods of producing same
06/03/1999WO1999026942A1 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
06/03/1999WO1999026940A2 Method for producing 8-methoxy-quinoline carboxylic acids
06/03/1999WO1999026666A2 Medical article with adhered antimicrobial metal
06/03/1999WO1999026664A1 Recombinant mycoplasma hyopneumoniae vaccine
06/03/1999WO1999026656A1 Monoclonal human natural antibodies
06/03/1999WO1999026654A1 Vaccines with an ltb adjuvant
06/03/1999WO1999026653A1 Dna vaccines against tick-borne flaviviruses
06/03/1999WO1999026651A1 ribH
06/03/1999WO1999026650A1 ribB
06/03/1999WO1999026647A1 Use of heparin-binding protein for the modulation or prophylaxis of apoptosis of mammalian cells
06/03/1999WO1999026632A1 Phospholipids having antimicrobial activity with or without the presence of antimicrobials
06/03/1999WO1999026476A1 New psoralens for pathogen inactivation
06/03/1999WO1999026475A1 ribG
06/03/1999WO1999018996B1 Enterococcus antigens and vaccines
06/03/1999WO1999016466A3 Vaccine compositions and methods of enhancing vaccine efficacy
06/03/1999WO1999013894A3 Use of ifn-alpha and amantadine for the treatment of chronic hepatitis c
06/03/1999WO1999012951A8 Uses of nicotinamide adenine dinucleotide and its analogs for treatment of malignant and infectious diseases
06/03/1999WO1999006422A3 Base analogues
06/03/1999WO1998037089A8 Matrix derived anti-hiv peptides and transdominant proteins
06/03/1999CA2316340A1 Phospholipids having antimicrobial activity with or without the presence of antimicrobials
06/03/1999CA2311759A1 Recombinant mycoplasma hyopneumoniae vaccine
06/03/1999CA2311581A1 Nucleoside analog compositions and uses thereof
06/03/1999CA2311472A1 Desaturase genes and their use
06/03/1999CA2310561A1 Virulence-associated nucleic acid sequences and uses thereof
06/03/1999CA2310217A1 Extracellular matrix-binding proteins from staphylococcus aureus
06/03/1999CA2309358A1 A-33 related antigens and their pharmacological uses
06/02/1999EP0919628A1 Process for producing high-molecular-weight compounds of phenolic compounds, etc. and use thereof
06/02/1999EP0919568A1 Escape mutant of the surface antigen of hepatitis B virus
06/02/1999EP0919566A2 Antimicrobial peptides and their use against plant pathogens
06/02/1999EP0919562A1 Phosphonate nucleotide compounds
06/02/1999EP0919243A1 Vaccine containing B subunits of heat-labile enterotoxin (LTB) of Escherichia coli as an adjuvant
06/02/1999EP0918875A1 Novel internal ribosome entry site and vector containing same
06/02/1999EP0918870A1 Chitinase materials and methods
06/02/1999EP0918796A1 Monoclonal antibody which agglutinates e. coli having the cs4-cfa/i family protein
06/02/1999EP0918787A1 Compositions and methods for antisense inhibition of protein translation
06/02/1999EP0918783A1 6-o-substituted erythromycins and method for making them
06/02/1999EP0918771A1 Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase
06/02/1999EP0918770A1 Pyridyl-piperazinyl-phenyl-oxazolidinone derivatives and their use as antibacterials
06/02/1999EP0918769A1 Substituted piperazinyl-phenyl-oxazolidinone derivatives and their use as anti-bacterial agents
06/02/1999EP0918746A1 Immunotherapeutic agents and their use in the reduction of cytokine levels
06/02/1999EP0918742A1 Water-miscible esters of monoglycerides having antimicrobial activity
06/02/1999EP0918540A1 Intradermal bovine polynucleotide vaccine
06/02/1999EP0918537A1 Use of proteolytic enzymes for influencing cytokines
06/02/1999EP0918533A2 Anti-chlamydial methods and materials
06/02/1999EP0918528A1 Method for treating gastrointestinal damage
06/02/1999EP0918520A1 Process for preparing potassium clavulanate
06/02/1999EP0918458A1 Antimicrobial treatment for herpes simplex virus and other infectious diseases
06/02/1999EP0845036B1 Functional role of adrenomedullin (am) and the gene-related product (pamp) in human pathology and physiology
06/02/1999EP0748310B1 Diesters of carbonic acid endowed with antiviral and anti-inflammatory activity
06/02/1999DE19752700A1 1-Deoxy-D-xylulose-5-phosphate synthase protein and modulators
06/02/1999CN1218513A Vectors based on recombinant defenctive viral genmoes, and their use in formulation of vaccines
06/02/1999CN1218478A Cyclic adhesion inhibitors
06/02/1999CN1218473A Naphthyridine derivatives and their analogues inhibiting cytomegalovirus
06/02/1999CN1218465A 2,4-diaminopyrimidine derivatives
06/02/1999CN1218410A Use of IL-12 and IFN-'alpha' for treatment of infections diseases
06/02/1999CN1218409A Stimulation of host defence mechanisms against viral challenges
06/02/1999CN1218408A Method of treatment
06/02/1999CN1218406A HLA-A2.1 binding peptides and their uses
06/02/1999CN1218403A Formulation for use in prevention of pathogen induced diseases including HIV and HSV
06/02/1999CN1218397A Ethene containing solutions and use thereof in methods of therapy or prophylaxis
06/02/1999CN1218395A Buccal delivery system
06/02/1999CN1218368A Method for treating common cold or allergic rhinitis
06/02/1999CN1218057A New immunological activity for peptide of limulus anti-LPS factor
06/01/1999US5908933 Certain 4H- 1!benzopyrano 3,4-b!pyridine derivatives and their corresponding 6,7-b! and 7,8-b! ring isomers
06/01/1999US5908923 Method of using transdominant negative retroviral integrase in the treatment of retroviral infection
06/01/1999US5908845 Polyether nucleic acids
06/01/1999US5908841 5,11-dihydro-6H-dipyrido 3,2-b:2',3'-e!azepine-6-ones and their use in the prevention of treatment of HIV infection
06/01/1999US5908837 Antiinflammatory agent
06/01/1999US5908780 Cells transformed or transfected with HCMV US2 gene
06/01/1999US5908630 Toxin secreting bacteria; pneumonia
06/01/1999US5908629 Polysaccharide-protein complex
06/01/1999US5908626 Genetic engineering
06/01/1999US5908621 Polyethylene glycol modified interferon therapy
06/01/1999CA2251260A1 Escape mutant of the surface antigen of hepatitis b virus
1 ... 1509 1510 1511 1512 1513 1514 1515 1516 1517 1518 1519 1520 1521 1522 1523 1524 1525 1526 1527 1528 1529 ... 1798